Gemphire Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications, as well as nonalcoholic fatty liver disease. Co.'s product candidate, gemcabene, has been tested as monotherapy and in combination with statins and other drugs. Within dyslipidemia, indications include Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia and Nonalcoholic Steatohepatitis. We show 16 historical shares outstanding datapoints in our coverage of GEMP's shares outstanding history.
Understanding the changing numbers of GEMP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like GEMP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching GEMP by allowing them to research GEMP shares outstanding history
as well as any other stock in our coverage universe. |
Free GEMP Email Alerts:
Video: Shares Outstanding Importance
